Phase 2 Small Cell Lung Cancer trials recruiting now

All Small Cell Lung Cancer trials, every phase

Other phases for Small Cell Lung Cancer

Phase 2 Small Cell Lung Cancer trials

• 68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer
  NCT07508852 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
  NCT07253142 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 10 locations
• A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD-L1 Inhibitor, Carboplatin, and Etoposide as First-Line Treatment in Patients With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
  NCT07373964 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
  NCT06095505 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer
  NCT05924841 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of DC05F01 in Chinese Patients with Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors
  NCT06873555 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
  NCT07174583 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
  NCT07208773 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
  NCT06780137 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 48 locations
• Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab
  NCT06771518 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor
  NCT03093688 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
  NCT05800587 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer
  NCT06283719 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Dose-escalated Adaptive Radiotherapy of Thoracic Disease for Small Cell Lung Cancer
  NCT04952480 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
  NCT05068232 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Hypofractionated Radiotherapy Combined with Immunotherapy for Limited-stage Small-cell Lung Cancer
  NCT06527898 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer
  NCT04951947 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer
  NCT05903092 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer
  NCT04539977 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
  NCT04199741 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
  NCT05363280 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Phase 2 Study of Fingolimod in Lung Cancers
  NCT06424067 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC
  NCT06769971 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• SKB500 Combinations in Patients With Small Cell Lung Cancer
  NCT07296809 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
  NCT06047379 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Serplulimab Combined With CCRT for LS-SCLC.
  NCT06295926 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)
  NCT07155200 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of GV20-0251 in Participants With Solid Tumor Malignancies
  NCT07070518 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
  NCT05450965 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Study of Trilaciclib and Lurbinectidin
  NCT05578326 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
  NCT05978284 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance Status
  NCT07803848 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
  NCT07476287 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• Tarlatamab for SCLC Brain Metastases
  NCT07402343 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study
  NCT07583511 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
  NCT04585750 · Phase: Phase 1, Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · 154 locations

Common questions

What does Phase 2 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.